BROAD SCOPE OF ADVANTAGES
Partnering with Calvert Research Institute offers a deep set of advantages to both investors and emerging enterprises:

• Funding is spread among numerous drug candidates in differing areas of science, which reduces both scientific and financial risk for investors.
• Calvert Research Institute is connected with numerous companies with a wide range of expertise. Having multiple voices involved in decision-making and planning ensures that the very best possible CRI candidates are selected and supported.
• The CRI companies include a high level of nutraceutical, biotechnical, pharmaceutical, and medical device talent spanning all levels of analytical science. We also include a high degree of business development, management, media and marketing experience and abilities.
• Because CRI partners invest financial and professional resources in the technologies selected, we share risk associated with our decisions alongside outside venture supporters.
• In addition to investing our own funds and resources, CRI has additional fund-raising and capital acquisition capabilities within our group. This enables our developing company clients to preserve their capital and obtain all the elements that can make their business successful in a "one stop shopping" environment.
• Since our primary investment space supports developing companies up to Phase IIB, general valuation improvements can create very attractive fund returns.
• CRI partner companies are not only experienced but are also financially strong businesses.